Cagrilintide vs CJC-1295

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

Cagrilintide is a long-acting synthetic amylin analogue under clinical development for obesity, designed to mimic the satiety-promoting and gastric-emptying-reducing actions of the endogenous beta-cell hormone amylin. By activating amylin receptors in the hindbrain, cagrilintide reduces caloric intake and body weight, and the drug is also being co-developed with the GLP-1 receptor agonist semaglutide (CagriSema) to target multiple appetite-regulating pathways simultaneously. Phase 2 randomized controlled trials published in The Lancet have demonstrated meaningful weight reduction in people with overweight and obesity, establishing proof of concept for both monotherapy and combination approaches. Cagrilintide is an investigational compound that has not yet received FDA approval; it remains in late-stage clinical development as of 2025.

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 (DAC-GRF) is a synthetic 30-amino-acid GHRH analog incorporating a Drug Affinity Complex (DAC) modification — trans-4-aminomethylcyclohexane carboxylic acid — that enables covalent binding to circulating albumin, dramatically extending the plasma half-life from minutes (as with native GHRH) to approximately 6–8 days and enabling once or twice-weekly dosing for sustained GH and IGF-1 elevation. The extended half-life allows CJC-1295 to act as a continuous GHRH-receptor agonist at pituitary somatotrophs rather than producing pulsatile stimulation, stimulating cumulative GH secretion and downstream IGF-1 production; this pharmacokinetic profile distinguishes it from short-acting GHRH analogs such as sermorelin and positions it for research in GH axis restoration. A Phase 1 dose-escalation RCT in healthy adults published in the Journal of Clinical Endocrinology and Metabolism (2006) demonstrated dose-dependent and sustained increases in mean GH and IGF-1 concentrations following single-dose administration, establishing the only indexed human pharmacokinetic and pharmacodynamic data for this compound; all other indexed literature consists of anti-doping detection methods. CJC-1295 has no FDA approval and no approved therapeutic indication in any jurisdiction; it is available only as a research compound and the clinical evidence base is limited to a single Phase 1 safety and PK study in healthy subjects, with no Phase 2 or Phase 3 data addressing efficacy for any specific indication. CJC-1295 and ipamorelin combination: CJC-1295 is most commonly studied in combination with ipamorelin, a selective GHRP (growth hormone-releasing peptide), because the two compounds act on complementary pathways to stimulate GH release. CJC-1295 activates the GHRH receptor at pituitary somatotrophs, providing a sustained permissive signal for GH secretion; ipamorelin activates the ghrelin receptor (GHS-R1a), producing a discrete GH pulse with high selectivity and without meaningfully elevating cortisol or prolactin. Research and clinical interest in the combination centers on the synergistic GH pulse amplitude achieved when both pathways are stimulated together — greater than either compound alone. The pharmacokinetic profiles are complementary: CJC-1295's extended half-life (6–8 days) provides a stable GHRH background, while ipamorelin's short half-life (approximately 2 hours) allows timed pulsatile stimulation. In clinical research contexts, CJC-1295 is typically administered subcutaneously one to two times weekly to maintain a sustained GH baseline, while ipamorelin is dosed more frequently — daily or multiple times per day — to generate GH pulses aligned with sleep or exercise. A triple-stack combining CJC-1295, ipamorelin, and sermorelin is referenced in some clinical contexts for additive GH axis stimulation, though evidence supporting the triple combination beyond individual compound data is limited. All dosing references are for research contexts only; no approved clinical protocols exist for any of these combinations. Subcutaneous vs intramuscular injection for CJC-1295: CJC-1295 is administered exclusively via subcutaneous injection in all published research — intramuscular injection is not used for this compound. Subcutaneous injection into abdominal fat or thigh tissue results in slower, more consistent absorption suitable for the depot-like pharmacokinetic profile that CJC-1295's DAC modification already provides. Rotation of injection sites is recommended to avoid lipohypertrophy at repeated injection locations. Injection technique, site preparation with an alcohol swab, and proper needle gauge selection (typically 27–31G for subcutaneous peptide injection) are standard considerations across all subcutaneous peptide administration contexts.